Investors are advised that this news is based on a press release statement from Cyclerion Therapeutics (NASDAQ:CYCN), Inc. and should consider the inherent uncertainties of forward-looking statements. Based on InvestingPro's Fair Value analysis, the stock currently appears to be trading below its estimated Fair Value, though investors should note that analysts do not anticipate profitability this year. Based on InvestingPro's Fair Value analysis, the stock currently appears to be trading below its estimated Fair Value, though investors should note that analysts do not anticipate profitability this year. The biopharmaceutical company is refocusing its efforts to acquire new assets in the central nervous system (CNS) space and is looking to generate revenue from its existing soluble guanylate cyclase (sGC) stimulator assets to avoid near-term dilution.
Under the revised agreement with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments for praliciguat, an sGC stimulator. Akebia will take over intellectual property expenses after Q1 2025, with Cyclerion eligible for up to approximately $560 million in potential future payments plus tiered sales-based royalties.
Additionally, Cyclerion entered into an exclusive license option agreement for another sGC stimulator, olinciguat, with an entity controlled by CVCO Therapeutics. The potential partner will evaluate olinciguat during the option period and cover ongoing intellectual property-related costs.
Investors are advised that this news is based on a press release statement from Cyclerion Therapeutics, Inc. and should consider the inherent uncertainties of forward-looking statements. Based on InvestingPro's Fair Value analysis, the stock currently appears to be trading below its estimated Fair Value, though investors should note that analysts do not anticipate profitability this year.
Dr. Regina Graul, President and CEO of Cyclerion, expressed confidence in the company's direction and the potential of the newly evaluated assets to become the foundation for the company's future.
The company's statements contain forward-looking information that involves risks and uncertainties, and actual results may differ materially from projections. Cyclerion has cautioned that while they base their plans on current knowledge, future events may not unfold as predicted.
Investors are advised that this news is based on a press release statement from Cyclerion Therapeutics, Inc. and should consider the inherent uncertainties of forward-looking statements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.